Pathology back 👉 it's cancer

What I had done

The biopsy was Friday (16 needle samples from across the prostate, four of them aimed at the area the MRI flagged). Pathology was supposed to take five business days. It came back today — one business day later.

What the pathology found

The 16 samples were sorted into 13 specimen containers by location. Three of the 13 contain cancer: two on the right side of the gland (the right mid PZPL and right lateral) and one at the midline base.

The grade is Grade Group 2 (also written as Gleason 3+4=7). On a scale of 1 to 5 — where 1 is the lowest-risk cancer, often just watched, and 5 is the most aggressive — this is the second-lowest. The cancer cells are mostly the less-aggressive pattern with a smaller amount of the more-aggressive pattern mixed in.

Two additional findings change the picture, though. The pathologist identified intraductal carcinoma (cancer cells filling pre-existing prostate ducts) in one sample and cribriform pattern (cancer cells arranged in a sieve-like shape) in two others. Both are known to behave more aggressively than the Grade Group number alone would predict. They don't change the grade. They shift the risk category.

What this does (and doesn't) mean

It means treatment is the path forward. With the intraductal and cribriform findings in the report, active surveillance — monitoring without treating — is off the table. Most current guidelines treat either feature as a reason to move to definitive treatment.

It does not mean the cancer has spread. The MRI showed nothing in the lymph nodes, seminal vesicles, or bones, and the biopsy showed no clear extension beyond the gland itself. As far as we know, this is localized.

It also doesn't mean a single treatment path is preordained. Surgery and radiation produce broadly equivalent outcomes for localized cancer at this stage. The differences are in side effects, recovery, and lifestyle. That conversation starts tomorrow.